mirabegron + propiverine

Mirabegron + propiverine is a **fixed-dose combination** of two oral pharmaceuticals used to treat **overactive bladder (OAB)** that is resistant to monotherapy. Mirabegron is a small molecule **beta-3 adrenergic receptor agonist** that relaxes the detrusor muscle of the bladder, increasing bladder capacity and reducing symptoms such as urgency and frequency. Propiverine is a small molecule **antimuscarinic agent** that reduces involuntary detrusor contractions by antagonizing muscarinic receptors in the bladder. The combination targets complementary pathways, providing increased efficacy in patients who do not respond to single-agent therapy. Clinical studies indicate that this combination effectively reduces OAB symptoms, including urge incontinence, frequency, and nocturia, with an acceptable safety profile[1][2].